TICKERNERD
Menu
KMDAKMDAHealthcare · Drug Manufacturers - Specialty & Generic

KMDA Stock Forecast: Kamada Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$8.24
+2.74% on the day

The 3 Wall Street analysts covering Kamada Ltd. hold a median 12-month price target of $14 — +69.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$462.7M
Ticker Nerd rank
95 / 100
Median analyst target
$14
Analysts covering
3
Total return, dividends reinvested
1W
+8.7%
1M
+13.2%
YTD
+20.0%
1Y
+20.2%
From 52W high
−9.0%
From 52W low
+28.4%
$6.42
$9.06
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KMDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kamada Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
95 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
94
Volatility
88
Revisions
82
Momentum
63
Growth
62
Accruals
55
Size
54
Issuance
45

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (45): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KMDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KMDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$6.00$8.00$10.00$12.00$14.00$16.00Oct 25Jan 26Apr 26Jul 26KMDAHigh $15Median $14Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $11Median $14High $15

The green dot is the last close — the median target sits +69.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Dec 2025HC Wainwright & Co.MaintainsBuy$11 → $13
15 May 2025BenchmarkReiteratesBuy—
21 Mar 2025BenchmarkInitiatesBuy—
6 Mar 2025HC Wainwright & Co.ReiteratesBuy—
10 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
3 July 2024StifelInitiatesBuy—
9 May 2024HC Wainwright & Co.ReiteratesBuy—
7 Mar 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2023HC Wainwright & Co.ReiteratesBuy—
17 Aug 2023HC Wainwright & Co.ReiteratesBuy—
25 May 2023HC Wainwright & Co.ReiteratesBuy—
16 Mar 2023HC Wainwright & Co.ReiteratesBuy—
2 Feb 2018Chardan CapitalInitiatesBuy—
13 Nov 2015JefferiesMaintainsBuy—
25 June 2013JefferiesInitiatesBuy—
25 June 2013Morgan StanleyInitiatesEqual-Weight—
25 June 2013OppenheimerInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KMDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KMDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+10.8%
Analysts raising
0
Analysts cutting
4
Fundamentals

Kamada Ltd. (KMDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.5×

Cheaper than 36% of US stocks

Price / sales
2.6×

Cheaper than 46% of US stocks

Price / book
1.8×

Cheaper than 50% of US stocks

EV / EBITDA
8.9×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
2.8%

Higher than 34% of US stocks

Earnings growth (YoY)
4.2%

Higher than 41% of US stocks

Gross margin
42.3%

Higher than 53% of US stocks

Operating margin
15.4%

Higher than 73% of US stocks

Net margin
11.2%

Higher than 72% of US stocks

Returns & dividend
Return on equity
8.0%

Higher than 59% of US stocks

Return on assets
4.2%

Higher than 72% of US stocks

Dividend yield
8.3%

Higher than 89% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KMDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
KMDAKamada Ltd.$462.7M
95
CGCCanopy Growth Corp.$474.5M
48
EOLSEvolus, Inc.$545.9M
87
BIOABioAge Labs, Inc.$420.7M
41
AQSTAquestive Therapeutics, Inc.$584.9M
50
TKNOAlpha Teknova, Inc.$394.6M
93
TLRYTilray Brands, Inc.$659.2M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kamada Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KMDA news & analysis

Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026

GlobeNewsWire · 17 Aug 2026positive

Kamada declared a cash dividend of $0.17 per share, consistent with its cash dividend policy. The company also reported record-high revenue and profitability for the first six months of ​2026.

Why it matters — A KMDA watcher would care because the dividend declaration and record revenue and profitability signal strong financial performance for the ​the company.</ ​

Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks Investment Research · 14 Aug 2026positive

Zacks Investment Research published a piece identifying Kamada (KMDA) as a solid growth stock, citing three reasons why the company's growth attributes could help it outperform the market.

Why it matters — The article signals favourable analyst views on Kamada's growth potential, which KMDA watchers would take into account when assessing the stock.

KMDA or PRTA: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 14 Aug 2026neutral

Zacks Investment Research published a comparison of Kamada (KMDA) and Prothena (PRTA), examining which of the two biomedical and genetics stocks represents a better value for investors seeking undervalued companies.

Why it matters — KMDA watchers would care because the article positions Kamada as a potential value opportunity relative to a peer in the same sector, which could influence investor perception of the stock.

Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet

Zacks Investment Research · 14 Aug 2026positive

Zacks Investment Research notes that the consensus price target for Kamada (KMDA) implies roughly 79.1% upside potential, while also observing that such price-target metrics are generally not highly effective. The article highlights that an upward trend in earnings estimate revisions could indicate near-term upside for the stock.

Why it matters — A KMDA watcher would care because the report points to improving earnings estimate revisions as a potential signal of near-term momentum for the stock.

Should Value Investors Buy Kamada (KMDA) Stock?

Zacks Investment Research · 13 Aug 2026neutral

Zacks published a piece headlined "Should Value Investors Buy Kamada (KMDA) Stock?" that describes the firm's Zacks Rank system, which emphasises earnings estimates and estimate revisions, alongside value, growth, and momentum trends to identify strong stocks. The article presents this evaluation framework without stating specific findings on Kamada.

Why it matters — A KMDA watcher would care because it indicates the company is receiving analytical coverage from Zacks' widely followed stock-evaluation methodology.

FAQ

Frequently asked questions about KMDA stock

What is the KMDA stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Kamada Ltd. have a median 12-month price target of $14, with estimates ranging from $11 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KMDA stock a buy right now?

Of the 3 analysts covering Kamada Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kamada Ltd. 95 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KMDA?

As at 22 Aug 2026, Kamada Ltd. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will KMDA stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +69.9% from the last close, and Ticker Nerd's factor model ranks Kamada Ltd. 95 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KMDA stock forecast for 2030?

No analyst covering Kamada Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KMDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $15 over the next 12 months.

How has KMDA stock performed over the past year?

Kamada Ltd. returned +20.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kamada Ltd. do?

Kamada Ltd. is a biopharmaceutical company specializing in the development, production, and marketing of specialty plasma-derived protein therapeutics.

What is the latest news on KMDA?

The most recent item we track (GlobeNewsWire, 17 Aug 2026): "Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026". Kamada declared a cash dividend of $0.17 per share, consistent with its cash dividend policy. The company also reported record-high revenue and profitability for the first six months of ​2026.

Company

About Kamada Ltd.

Kamada Ltd. is a biopharmaceutical company specializing in the development, production, and marketing of specialty plasma-derived protein therapeutics. Its primary purpose is to provide innovative medical solutions for unmet clinical needs, particularly in the fields of immunology, respiratory diseases, and critical care. Kamada’s portfolio includes a range of products, such as Alpha-1 Antitrypsin (AAT) for the treatment of Alpha-1 Antitrypsin Deficiency and a variety of hyperimmunoglobulins targeting infectious diseases. The company significantly impacts the healthcare sector by offering therapies that address rare and life-threatening conditions, thus contributing to advancements in patient care and quality of life. Kamada Ltd.'s role in the financial markets is notable for its focus on R&D-driven growth, with an array of advanced products in its pipeline aimed at broadening therapeutic applications. Headquartered in Israel, Kamada distributes its products internationally, collaborating with multinational healthcare companies and leveraging a robust supply chain for global market access. Its contributions to the biopharmaceutical industry highlight its commitment to expanding the reach of essential therapeutic options worldwide.

462 employees · Israel · https://www.kamada.com